Figure 2. Anti-Qβ must be present for CMP-001 to induce anti-tumor responses in mice and cytokine production from splenocytes.

A, Treatment schema of WT or Jh−/− Balb/c mice injected SC with CMP-001 (Primed; WT and Jh−/−) or saline (Not Primed; WT) prior to A20 tumor implantation into one flank, collection of serum and subsequent IT CMP-001 treatment. B, Ig anti-Qβ titers in mouse serum detected 10 days after SC administration of CMP-001 (Primed; WT and Jh−/−) or saline (Not Primed; WT); data is representative of 2 replicate experiments; n=5 mice per group. C, Kaplan-Meier survival curves of IT CMP-001 treated WT and Jh−/− Primed and WT Not Primed mice (data is from 2 replicate experiments; n=10–15 mice per group). D, Cytokine levels produced by murine splenocytes cultured with or without CMP-001 and immune serum (data is from one experiment; n=3 replicates per experimental group). Survival data were analyzed using the Logrank test and cytokine data were analyzed using a one-way ANOVA with Tukey’s multiple comparisons test.